CompletedPhase 3ACTRN12605000058673
Magnesium in Aneurysmal Subarachnoid Haemorrhage
A multi-centre, single blinded, randomised controlled trial of two target ranges for serum magnesium in patients with Subarachnoid Haemorrhage to reduce vasospasm
Sponsor
Pharmalab
Enrollment
190 participants
Start Date
Jan 1, 2010
Study Type
Interventional
Conditions
Summary
Patients had a reduced incidence of vasospasm but the resul was not significant. There was no difference between groupw
Eligibility
Sex: Both males and femalesMin Age: 18 Yearss
Inclusion Criteria1
- <72 hours since haemorrhage
Exclusion Criteria1
- /Traumatic SAH. 2/Creatinine >0.2mmol/l. 3/Myasthenia Gravis. 4/Death imminent. 5/Vasospasm present on hospital admission.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Magnesium sulfate (20ml/hr). The concentration of magnesium will be titrated to the serum magnesium level in order to achieve a serum level of 1.6-2.5mmol/L, in the treatment group.
Magnesium sulfate (20ml/hr). The concentration of magnesium will be titrated to the serum magnesium level in order to achieve a serum level of 1.6-2.5mmol/L, in the treatment group.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000058673